Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.